This review aims to dissect the current knowledge on the interplay between RHAMM and ncRNAs in cancer, while also exploring therapeutic potentials arising from peptide inhibitors, HA oligomers, antibody-based strategies, and peptide vaccines targeting RHAMM. Here, HMMR is linked to cancer.